The decision date for a NDA for a new hepatitis B vaccine, Dynavax’s Heplisav-B, has been delayed, as the FDA asked for more post-marketing study information on the vaccine.
The decision date for a New Drug Application (NDA) for a new hepatitis B vaccine, Heplisav-B—commercially owned by Dynavax Technologies—was originally scheduled for Thursday, August 10, 2017, however, the ruling was delayed by the US Food and Drug Administration on August 3rd.
The FDA has requested more post-marketing study information for the vaccine, which can potentially delay the decision for up to 3 months.
Though Heplisav-B received support from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) in the form of a 12 to 1 vote to approve the vaccine’s licensure safety data in late July, the administration indicated feedback from VRBPAC led to their believing that “more time is required to finalize key details of post-marketing study,” according to a Dynavax press release.
A briefing document of the advisory meeting reported clinical trial data indicating an imbalance in adverse cardiac events “unexpected” for the vaccine. The Heplisav-B trial also reported more trial patient deaths (34) versus comparable market HBV vaccines (8), with a majority of the patients having had “significant pre-existing conditions, comorbidities, or contributory social circumstances.”
This is far from the first hurdle Heplisav-B has had to overcome on its track to the market. Since submitting its Biologic License Application (BLA) in April 2012, Dynavax has undergone 2 VRBPAC advisory meetings. The first — in November 2012 — returned a 13 to 1 vote to approve Heplisav-B’s data for demonstrating immunogenicity.
However, the committee also ruled there was insufficient data to support the vaccine’s safety.
The FDA then submitted a Complete Response Letter (CRL) to Dynavax in February 2013, stating the BLA’s data needed further safety evaluation for its indicated 18- to 70-year age group in the phase 3 trial results of the vaccine.
A second CRL to Dynavax in November 2016 requested clarification on the vaccine’s specific adverse events of special interest (AESIs), as well as new analyses of safety data.The data these clarifications called for consist of multiple clinical phase 3 trials of Heplisav-B, in which the investigational vaccine’s safety was studied on more than 14,000 participants.
However, more studies are anticipated. Eddie Gray, chief executive officer of Dynavax, said in a press release announcing the FDA’s 3-month decision delay, that the company would work with third-party providers to develop an “appropriate study” that addressed the comments of the VRBPAC in their third and most recent advisory meeting.
Despite all of the red tape in its way, Heplisav-B has garnered attention for its market potential. The twice-a-month injection vaccine is advertised as a HBV surface antigen-Receptor 9 agonist combinant drug that enhances immune response in patients. In phase 3 trials, adult patients showed greater, easier protection in fewer doses of Heplisav-B versus currently marketed vaccines.
Dynavax Technologies’ shares raised 72% on the Monday after the VRBPAC’s safety approval vote in late July. The interest in the vaccine — beyond its lessened dosage and improved efficacy — comes from a mindset of necessity.
Tom Nealon, chief executive officer of the American Liver Foundation, explained the stakes of HBV—one of the most common liver infections in US patients that could potentially lead to hepatocellular carcinoma and the need for liver transplants.
“The potential FDA approval of the Hepsilav-B vaccine would provide another option to help protect against the spread of HBV,” Nealon said. “Access to effective vaccines can help protect millions of Americans from contracting this disease, which can ultimately lead to fewer cases of hepatocellular carcinoma and reduce the need for liver transplants.”
Though the drug has spent a half-decade in regulatory limbo, Dynavax has remained confident. The company stated its most recent delay does not deter plans to commercially launch Heplisav-B in early 2018.
“We plan to respond to the request for additional information expeditiously,” Gray said. “We look forward to bringing this important vaccine to market to support the elimination of hepatitis B infection as a public health problem."